The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 4070 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 January 2024 | For information, tislelizumab has now been acquired by the company Beigene. NICE are liaising with the company regarding appropriate timelines for this appraisal and further information will be available in due course. |
| 01 August 2023 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 09 November 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 26 August 2022 | Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early March 2023. |
For further information on our processes and methods, please see our CHTE processes and methods manual